Hartnup disorder is an autosomal recessive abnormality of renal and gastrointestinal neutral amino acid transport. A corresponding transport activity has been characterized in kidney and intestinal cells and named system B 0 . The failure to resorb amino acids in this disorder is thought to be compensated by a protein-rich diet. However, in combination with a poor diet and other factors, more severe symptoms can develop in Hartnup patients, including a photosensitive pellagra-like skin rash, cerebellar ataxia and other neurological symptoms. Homozygosity mapping in a Japanese family and linkage analysis on six Australian pedigrees placed the Hartnup disorder gene at a locus on chromosome 5p15. This fine mapping facilitated a candidate gene approach within the interval, which resulted in the cloning and characterization of a novel member of the sodium-dependent neurotransmitter transporter family (B 0 AT1, SLC6A19) from mouse
protein-rich diet. However, in combination with a poor diet and other factors, more severe symptoms can develop in Hartnup patients, including a photosensitive pellagra-like skin rash, cerebellar ataxia and other neurological symptoms. Homozygosity mapping in a Japanese family and linkage analysis on six Australian pedigrees placed the Hartnup disorder gene at a locus on chromosome 5p15. This fine mapping facilitated a candidate gene approach within the interval, which resulted in the cloning and characterization of a novel member of the sodium-dependent neurotransmitter transporter family (B 0 AT1, SLC6A19) from mouse
and human kidney, which shows all properties of system B 0 . Flux experiments and electrophysiological recording showed that the transporter is Na + dependent and Cl − independent, electrogenic and actively transports most neutral amino acids. In situ hybridization showed strong expression in intestinal villi and in the proximal tubule of the kidney. Expression of B 0 AT1 was restricted to kidney, intestine and skin. A total of ten mutations have been identified in SLC6A19 that co-segregate with disease in the predicted recessive manner, with the majority of affected individuals being compound heterozygotes. These mutations lead to altered neutral amino acid transport function compared to the wild-type allele in vitro. One of the mutations occurs in members of the original Hartnup family described in 1956, thereby defining SLC6A19 as the 'Hartnup'-gene.
Overview of amino acid transport in epithelial cells
Amino acids are resorbed in the small intestine by specific transport systems located in the apical membrane of intestinal enterocytes and are released into the portal vein by a set of different basolateral transport systems. The portal vein conveys amino acids to the liver, where they are used locally or delivered systematically as nutrients for other tissues. In the kidney an ultrafiltrate is produced that contains all low molecular weight compounds of the blood plasma. To avoid wastage of valuable nutrients in the urine, all nutrients are reabsorbed by the epithelial cells of the proximal tubules and delivered back into the blood. More than 95% of ultrafiltrated amino acids are cleared in the S1-S3 segments of the proximal tubule. In many cases it has been demonstrated that transport in intestinal enterocytes and kidney epithelial cells is carried out by similar transport systems. A consensus model of amino acid resorption across the apical membrane of kidney and intestinal epithelial cells (Figure 1 ) has been derived from three kinds of observations: (i) the phenotype of inherited aminoacidurias, (ii) transport experiments in perfused nephrons and brush-border memKey words: amino acid transport, Hartnup disorder, system NBB, system B0, SLC6A19. 1 To whom correspondence should be addressed (email stefan.broeer@anu.edu.au).
brane vesicles, and (iii) molecular cloning of amino acid transporters. Four different aminoacidurias can be discriminated: (i) cystinuria (OMIM 220100 and 600918), a defect of apical transport of cationic amino acids and cystine; (ii) Hartnup disorder (OMIM 234500), a defect of apical transport of neutral amino acids; (iii) iminoglycinuria (OMIM 242600), a defect affecting uptake of proline and glycine; and (iv) dicarboxylic aminoaciduria (OMIM 222730), a defect of anionic amino acid transport. It can be concluded from these defects that there are at least four major transport systems for proteinogenic amino acids in the kidney. The presence of these transport activities was confirmed by experiments using perfused nephrons and brush-border membrane vesicles (for reviews see [1] [2] [3] [4] . The transport activity for cationic amino acids and cystine was designated system b 0,+ , indicating a Na + -independent transporter for neutral and cationic amino acids. This transporter is an antiporter coupling the uptake of cationic amino acids and cystine to the efflux of neutral amino acids [5] . The Na + -dependent transport activity for neutral amino acids was termed system B 0 (or NBB); it mediates the transport of all neutral amino acids but has limited transport activity for glycine and proline [6] [7] [8] [9] [10] [11] . The transport of glycine and proline is mediated by the Na + -dependent IMINO system and the H + -dependent imino acid carrier [12, 13] . The transport activity for anionic amino acids was named system X AG , a Na + -dependent transporter for aspartate and glutamate [14, 15] . In the past twelve years, the existence of these functionally defined transport activities was confirmed by molecular cloning of the corresponding genes. EAAT3 (EAAC1) was identified as the glutamate/aspartate transporter (system X AG ) expressed in neurons and in the kidney [16] . Subsequently, it was demonstrated that system b 0,+ activity is achieved by the heterodimeric transporter rBAT/b 0,+ AT. Mutations in either one of rBAT or b 0,+ AT cause cystinuria, albeit with slightly different phenotypes [5] . The molecular identification of system B 0 is the topic of this mini review. The proton amino acid co-transporter PAT1 (SLC36A1) has recently been proposed to be the molecular correlate of the IMINO acid carrier [17] . Although functionally similar, the proton co-transport mechanism of PAT1 has to be reconciled with the reported Na + -dependence of the IMINO system [18] . In addition to these four major apical transporters for proteinogenic amino acids, a few minor transport activities have been described for selected amino acids such as glycine and glutamine [1] . Significant apical transport activities have also been described for taurine and other β-amino acids but are not further described here.
Release of amino acids from epithelial cells into the blood is mediated by basolateral transport systems, which are different from those observed in the apical membrane (Figure 1) . Release of cationic amino acids across the basolateral membrane is mediated by the heteromeric antiporter 4F2hc/ y + LAT1. Mutations in y + LAT1 result in lysinuric protein intolerance (OMIM 222700). The disorder resembles deficiencies of urea cycle enzymes, because arginine is not available to compensate for the depletion of urea cycle intermediates [19] . The release of neutral amino acids at the basolateral membrane has not been clarified completely. The heteromeric amino acid transporter 4F2hc/LAT2 is located in the basolateral membrane of kidney epithelial cells [20] . This transporter is an obligatory antiporter and as a result cannot mediate net efflux of neutral amino acids. However, it is likely that it plays a role in the balanced release of neutral amino acids. Net efflux of neutral amino acids may occur via 4F2hc-independent LAT transporters of the SLC43 family.
Identification of the Hartnup disorder gene
Hartnup disorder was first described in two siblings of the Hartnup family in 1956 [21] , who were admitted to hospital with relatively severe symptoms including cerebellar ataxia, tremor, nystagmus, skin rash and delayed intellectual development. Similar cases were reported prior to that date in the literature, but were misdiagnosed as cases of pellagra (niacin deficiency). The link between the vitamin deficiency and Hartnup disorder is most likely a deficiency of the aromatic amino acid tryptophan. Approximately half of the NAD(P)H biosynthesis in humans is generated through tryptophan. As a result tryptophan and niacin deficiencies are thought to generate similar symptoms [22] . In agreement with this notion skin rashes in Hartnup disorder have been reported to respond to nicotinic acid supplementation.
Soon after its initial description it was suggested that Hartnup disorder results from a tissue-specific failure to resorb neutral amino acids in the kidney and intestine [23, 24] . This was subsequently confirmed in a number of physiological studies, e.g. [25] . Other cell types such as fibroblasts and lymphocytes do not demonstrate altered amino acid transport [26, 27] .
Hartnup disorder displays a wide variety of phenotypes. Most patients will remain asymptomatic, however, a limited number will display symptoms such as low weight relative to healthy siblings, episodes of diarrhoea, pellagra-like rash, etc. [28] . It appears that symptoms most likely appear in individuals in whom plasma amino acid levels are lower than normal [29] . As a result it has been suggested that the Hartnup phenotype typically becomes apparent when environmental or genetic factors predispose individuals to a lack of amino acid uptake. In the family described in the original description two siblings had severe clinical symptoms, one had mild symptoms and one child was symptom free, despite the fact that all four had biochemical evidence for disease demonstrated by prominent aminoaciduria [21] . Resorption of peptides may partially compensate for the lack of amino acid transport in Hartnup disorder. Thus the phenotypic variability may result from a number of factors including differential resorption, allelic and genetic heterogeneity, modifier genes and dietary intake.
Homozygosity mapping by Nozaki et al. in consanguineous Japanese pedigrees demonstrated linkage of Hartnup disorder to chromosome 5p15 [30] . A candidate gene survey carried out by the authors on chromosome 5p15 revealed several members of the SLC6 family comprising transporters for neurotransmitters, osmolytes and amino acids. These linked candidates included the dopamine transporter DAT (SLC6A3), the orphan transporter XT2 (SLC6A18) and a novel member of the SLC6 family (now SLC6A19). Linkage analysis in seven Australian families significantly narrowed the region to 7 cM on 5p15.33 containing both SLC6A18 and SLC6A19 and excluded four other functional candidates (SLC1A5, SLC3A2, SLC7A8 and SLC6A20) elsewhere in the human genome.
The sequence of SLC6A19 in the public human genome database was initially incorrect. Comparison of the human genome with the syntenic region on mouse chromosome 13 revealed a full-length transporter with significant similarity to other members of the SLC6 family. Cloning and expression of the mouse slc6a19 gene demonstrated that this transporter has all the properties of the amino acid transport system B 0 [31] . The transporter is Na + dependent, Cl − independent, electrogenic and transports all neutral amino acids. Substrates are accepted in the order Leu= =Val= =Ile= = Met > Gln= =Phe= =Ala= =Ser= =Cys= =Thr > His= =Trp= =Tyr= = Pro= =Gly. The order may change slightly with the species or the method employed. Interestingly, tryptophan, which is thought to be one of the key substrates in the development of the non-renal symptoms of Hartnup disorder is transported rather inefficiently. The affinity of B 0 AT1 for individual neutral amino acids lies between 0.6 and 1.0 mM. It has to be kept in mind, however, that the total concentration of neutral amino acids in the plasma ultrafiltrate is about 2 mM. As a result B 0 AT1 will be almost saturated in the early segments of the nephron.
The mouse B 0 AT1 gene is mainly expressed in kidney and intestine but expressed sequence tags (ESTs) of the transporter were also found in skin, thymus, spleen, uterus, haematopoietic stem cells, the diencephalon, inner ear and blood vessels [31] . In situ hybridization experiments revealed particularly strong expression in kidney cortex and small intestine. The staining in kidney cortex was compatible with expression of the transporter in segments S1-S2 of the proximal tubule. This also allows the transporter to remove neutral amino acids released in exchange for cationic amino acids by the rBAT/b 0,+ AT heterodimer (Figure 1 ). The expression of the human SLC6A19 gene was confirmed in these segments [32] . In the small intestine expression was confined to the villi; a gradient of expression was observed from the crypts towards the tip of the villi, consistent with a role of the transporter in amino acid resorption [31] .
The human SLC6A19 gene was cloned independently by two groups [32, 33] . It has the same transport properties as the mouse homologue. The expression pattern of human SLC6A19 is identical to that of the mouse transporter. Both studies demonstrated that mutations in SLC6A19 are associated with Hartnup disorder (Table 1 and Figure 2 ). By contrast no non-synonymous mutations were detected in SLC6A18, which lies next to SLC6A19 on chromosome 5. The requirement for two transport-impairing mutations for disease expression confirmed a recessive mode of inheritance. In seven Australian pedigrees six different mutations were identified that co-segregated with the disorder. In the Australian population the D173N mutation occurs at a frequency of 1 in 140 people. Four further mutations were identified in Japanese families (Table 1) . Interestingly, a splice donor mutation (IVS8 + 2G) detected in the original Hartnup family is identical to one detected in an apparently unrelated Australian pedigree. The definition of these mutations that disrupt neutral amino acid transport in affected individuals unambiguously defines SLC6A19 as the Hartnup disorder gene. 
